This trial is active, not recruiting.

Conditions increased drug resistance, infection resistant to quinolones and fluoroquinolones
Sponsor Sunnybrook Health Sciences Centre
Collaborator Novartis
Start date June 2010
End date December 2012
Trial size 168 participants
Trial identifier NCT01181713, SBK-OcuFResis


The purpose of this study is to determine if antibiotic resistance of the ocular surface flora to the 4th generation fluoroquinolones will increase after repeated use of topical antibiotics for three days post intravitreal injection.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective
No prophylactic antibiotic post intravitreal injection
Group treated with 3 day course of prophylactic topic antibiotic, fourth generation fluoroquinolones, after each intravitreal injection

Primary Outcomes

ocular flora resistance to 4th generation fluoroquinolone
time frame: 1 year

Eligibility Criteria

Male or female participants at least 65 years old.

Inclusion Criteria: - patients scheduled for intravitreal injection for neovascular age-related macular degeneration (ARMD) - 65 years or older - able to provide informed consent. Exclusion Criteria: - diagnosed with an active ocular, periocular or systemic infection - previously received treatment with an intravitreal injection - previously treated with antibiotics in the past three months - unable to attend the scheduled follow-up appointments or to complete treatment for any reason

Additional Information

Official title Antibiotic Resistance of Ocular Surface Flora After Continued Use of Topical Antibiotics Post Intravitreal Injections
Trial information was received from ClinicalTrials.gov and was last updated in December 2011.
Information provided to ClinicalTrials.gov by Sunnybrook Health Sciences Centre.